PMC:7696151 / 65084-65380
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1884 | 207-211 | Species | denotes | rats | Tax:10116 |
| 1898 | 15-18 | Chemical | denotes | HCQ | MESH:D006886 |
| 1899 | 274-277 | Chemical | denotes | HCQ | MESH:D006886 |
| 1919 | 179-202 | Disease | denotes | ventricular hypertrophy | MESH:D002312 |
| 1920 | 217-239 | Disease | denotes | pulmonary hypertension | MESH:D006976 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T118 | 179-202 | Phenotype | denotes | ventricular hypertrophy | http://purl.obolibrary.org/obo/HP_0001714 |
| T119 | 227-239 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T417 | 0-296 | Sentence | denotes | The ability of HCQ to interfere with the production of pro-inflammatory cytokines from monocytes and lymphocytes might underlie the observed improvements in systolic pressure and ventricular hypertrophy, in rats with pulmonary hypertension treated with 50 mg/kg/day i.p. of HCQ for 20 days [115]. |